30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
As the COVID-19 virus continues to spread, developers, contractors, and subcontractors are increasin...
Read More >
Seyfarth Synopsis: On February 18, 2020, Governor Phil Murphy announced proposed legislation amendin...
Read More >
On June 7, 2019, the Office of Environmental Health Hazard Assessment (OEHHA) announced that it has ...
Read More >
In order to structure physician practice management (“PPM”) and dental practice management (“DPM”...
Read More >
Great 401(k) Participant Features That Can Land You In Plan Sponsor Hot Water. It can get you in a b...
Read More >
In 2016, Florida joined the ranks of states that legalized medical marijuana after voters approved a...
Read More >